• Explore /
  • Poster
  • / Everolimus in combination with Octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 5-years update.

Everolimus in combination with Octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 5-years update.

Abstract Poster

Authors

null

Emilio Bajetta

Istituto di Oncologia, Policlinico di Monza, Monza, Italy

Emilio Bajetta , Laura Catena , Sara Pusceddu , Nicola Fazio , Italo Sarno , Giandomenico Di Menna , Lorenzo Dottorini , Anna Maria Marte , Carmela Turco

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4092)

DOI

10.1200/JCO.2016.34.15_suppl.4092

Abstract #

4092

Poster Bd #

84

Abstract Disclosures

Similar Posters

First Author: Emilio Bajetta

First Author: Nitya Prabhakar Raj

Poster

2014 Gastrointestinal Cancers Symposium

Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC).

First Author: Ghassan K. Abou-Alfa

First Author: Jia Fan